IP Library Granted Patent US 10,948,486
Granted Patent B2
US 10,948,486 · App. 15/490,795 · Granted Mar 16, 2021

Assay membrane and method of use thereof

Inventor: Sarita Kumble (Auckland, NZ)
Assignee: Pictor Limited
G01N33/54306B01L3/5025B01L3/5085B01L3/50855G01N33/543G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,948,486
App. No.
15/490,795
Granted
Mar 16, 2021
Kind
B2
Abstract

The present invention provides a microporous membrane for detecting at least one target analyte in a sample. The membrane includes an array that comprises at least one capture element and at least one control element printed on the membrane surface, at least one capture element corresponding to and being able to bind a target analyte, the plurality of control elements, when present including: i) at least one fiduciary marker, ii) at least one negative control to monitor background signal, iii) at least one negative control to monitor assay specificity, iv) at least one positive colorimetric control, and v) at least one positive control to monitor assay performance or any combination thereof.

Claims (31)

1. A method of detecting a target analyte comprising:

a) providing a microtiter plate having a plurality of wells, each well having a microporous membrane, each microporous membrane comprising an array of capture elements printed on the membrane surface, each capture element corresponding to and being able to bind a target analyte, the array further comprising at least one fiduciary marker and two or more control elements selected from the group consisting of:

i) at least one negative control to monitor background signal,

ii) at least one negative control to monitor assay specificity,

iii) at least one positive colourimetric control, and

iv) at least one positive control to monitor assay performance; and

b) contacting a microporous membrane of the microtiter plate with a sample such that a target analyte selectively binds a capture element and generates a detectable signal when the target analyte is present in the sample;

c) processing the microtiter plate using an automated system to detect binding of the target analyte to the capture element, wherein processing comprises:

i) orienting and gridding the array using the at least one fiduciary marker,

ii) detecting the at least one positive colourimetric control,

iii) monitoring assay performance using the at least one positive control, and

iv) detecting the target analyte by detecting intensity of the detectable signal, thereby detecting the target analyte.

2. The method of claim 1 , wherein the array of capture elements comprises a plurality of pairs of capture elements, each capture element in a pair being able to bind the same target analyte, each pair of capture elements being able to bind a different target analyte than any other pair of capture elements.

3. The method of claim 1 , wherein the capture elements are antigens.

4. The method of claim 3 , wherein the antigens are selected from one or more of Toxoplasma gondii , rubella virus, cytomegalovirus, herpes simplex virus type 1 and herpes simplex virus type 2.

5. The method of claim 1 , wherein the capture elements are antibodies or fragments thereof.

6. The method of claim 5 , wherein the capture elements specifically bind an antigen, wherein the antigen is selected from one or more of Toxoplasma gondii , rubella virus, cytomegalovirus, herpes simplex virus type 1 and herpes simplex virus type 2.

7. The method of claim 1 , wherein the target analyte is an antibody or fragment thereof.

8. The method of claim 7 , wherein the antibody is an IgG or IgM.

9. The method of claim 1 , wherein the target analyte is an antigen and the capture elements are antibodies or fragments thereof.

10. The method of claim 9 , wherein the antigen is selected from one or more of Toxoplasma gondii , rubella virus, cytomegalovirus, herpes simplex virus type 1 and herpes simplex virus type 2.

11. The method of claim 1 , wherein the target analyte and capture elements are antigens, or antibodies or fragments thereof.

12. The method of claim 11 , wherein the antibodies or fragments thereof specifically bind the antigens, wherein the antigens are selected from one or more of Toxoplasma gondii , rubella virus, cytomegalovirus, herpes simplex virus type 1 and herpes simplex virus type 2.

13. The method of claim 1 , wherein the microporous membrane is removably attached to a microtiter plate.

14. The method of claim 1 , wherein the microporous membrane comprises a plurality of arrays, each having capture elements printed on the membrane surface.

15. The method of claim 1 , wherein the capture elements comprise a polypeptide, carbohydrate, oligonucleotide or combination thereof.

16. The method of claim 15 , wherein the polypeptide is a glycoprotein.

17. The method of claim 1 , wherein the capture elements comprise a ligand.

18. The method of claim 1 , wherein the capture elements comprise a biomolecule.

19. The method of claim 1 , wherein the target analyte is a polypeptide, carbohydrate, lipid, virus, drug, oligonucleotide or combination thereof.

20. The method of claim 1 , wherein the target analyte is an antigen or fragment thereof.

Continuity (3)
Continuation 12513659
Provisional Application 60861771 · Nov 28, 2006
Related Publication 20180067109A1 · Mar 8, 2018
Cited By (1)
US 12,235,269